LEVOSIMENDAN to Facilitate Weaning From ECMO in Severe Cardiogenic Shock Patients
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 206 participants.
Also called NCT04728932
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 206 participants
- Registry
-
NCT04728932 -
2019-004319-29
-
- Other papers using this trial's data
- Levosimendan to Facilitate Weaning From ECMO in Patients With Severe Cardiogenic Shock: The LEVOECMO Randomized Clinical Trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- France
- Registry status
- Completed
Technical summary
Registry record NCT04728932. Randomized; triple masking; primary purpose treatment. Start 2021-08-27 (actual); primary completion 2024-11-09 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- LEVOSIMENDAN to Facilitate Weaning From ECMO in Severe Cardiogenic Shock Patients
- Acronym
- LEVOECMO
- Condition
- Cardiogenic Shock
- Condition
- Extracorporeal Membrane Oxygenation Complication
- Intervention (Drug)
- Levosimendan
- Intervention (Drug)
- Placebo of Levosimendan
- Lead sponsor
- Assistance Publique - Hôpitaux de Paris
Record details
- Record id
cardio:ct-nct04728932- Content hash
fc38b738caea6e060145e41c74de147b735ba4e4270c8d477a275ccb42432c0e